Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5038 - Impact of neoadjuvant therapy (NT) and pathological complete response (pCR) on breast-conserving surgery (BCS) in patients (pts) with breast cancer (BC): a meta-analysis.


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Breast Cancer


Carmen Criscitiello


Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362


C. Criscitiello1, M. Golshan2, W.T. Barry2, G. Viale1, S. Wong2, M. Santangelo3, G. Curigliano1

Author affiliations

  • 1 Division Of Experimental Therapeutics, Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 2 Breast Surgical Services, Dana Farber/Brigham and Women's Cancer Center, Boston/US
  • 3 Abdominal Surgery And Transplantation, Department Of Advanced Biomedical Sciences, University Federico II, Naples/IT


Abstract 5038


We performed a meta-analysis of randomized trials that evaluated the pCR and surgical decisions after NT for BC.


Studies were retrieved by searching the PubMed database and the proceedings of major conferences. The primary outcome was BCS rate. Secondary outcomes were pCR rate and association to BCS. Meta-analyses were performed using random-effects (RE) models that use inverse-variance weighting for each treatment arm based on the number of evaluable pts. Point estimates are reported with 95% confidence intervals, and p 


36 studies were identified (N = 12,311 pts). 17/36 studies reported both pCR and BCT for at least 1 treatment arm, and comprise the studies in this analysis. The number of arms per study ranged from 1 to 6, such that 42 independent units were available to evaluate the association between pCR and BCT. The BCS rate ranged from 5% to 76% across arms with an average BCS of 57% (95% CI 52%-62%). Significant heterogeneity was observed among the trials (Cochrane Q = 787, p 


This meta-analysis indicates that, despite increasing pCR, there is no concomitant increase in BCS. Future NT studies should reconsider using BCS as an endpoint.

Clinical trial identification

Legal entity responsible for the study

Carmen Criscitiello




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.